更新于：2024-09-05
Azilsartan
阿齐沙坦
更新于：2024-09-05
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 日本 (2012-01-18), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看首次获批时间轴
结构
分子式C25H20N4O5 |
InChIKeyKGSXMPPBFPAXLY-UHFFFAOYSA-N |
CAS号147403-03-0 |
关联
117
项与 阿齐沙坦 相关的临床试验Bioequivalence study of a randomized, open-label, single dose, fully replicate design of azilsartan 80 mg tablets between reference product (Edarbi) and azilsartan test product in Thai healthy volunteers under fasting condition
阿齐沙坦片在中国成年健康受试者中的生物等效性研究
阿齐沙坦片在中国健康受试者中单中心、随机、开放、单剂量、两制剂、两周期、两序列、双交叉、空腹和餐后状态下生物等效性试验
100 项与 阿齐沙坦 相关的临床结果
登录后查看更多信息
100 项与 阿齐沙坦 相关的转化医学
登录后查看更多信息
100 项与 阿齐沙坦 相关的专利（医药）
登录后查看更多信息
215
项与 阿齐沙坦 相关的文献（医药）2024-05-01Canadian journal of physiology and pharmacology
Azilsartan prevents muscle loss and fast- to slow-twitch muscle fiber shift in natural ageing sarcopenic rats
Article
作者: Kumar, Anand ; Mangrulkar, Shubhada ; Kushwaha, Sapana ; Chaple, D R ; Saraf, Shubhini A ; Prajapati, Priyanka
Sarcopenia is a musculoskeletal disease that reduces muscle mass and strength in older individuals. The study investigates the effects of azilsartan (AZL) on skeletal muscle loss in natural sarcopenic rats. Male Sprague-Dawley rats aged 4–6 months and 18–21 months were selected as young-matched control and natural-aged (sarcopenic) rats, respectively. Rats were allocated into young and old control (YC and OC) and young and old AZL treatment (YT and OT) groups, which received vehicles and AZL (8 mg/kg, orally) for 6 weeks. Rats were then sacrificed after muscle function analysis. Serum and gastrocnemius (GN) muscles were isolated for further endpoints. AZL significantly improved muscle grip strength and antioxidant levels in sarcopenic rats. AZL also restored the levels of insulin, testosterone, and muscle biomarkers such as myostatin and creatinine kinase in sarcopenic rats. Furthermore, AZL treatment improved the cellular and ultrastructure of GN muscle and prevented the shift of type II (glycolytic) myofibers to type I (oxidative) myofibers. The results showed that AZL intervention restored protein synthesis in natural sarcopenic rats by increasing p-Akt-1 and decreasing muscle RING-finger protein-1 and tumor necrosis factor alpha immunoexpressions. In conclusion, the present findings showed that AZL could be an effective intervention in treating age-related muscle impairments.
2023-11-24Medicine
Severe refractory hypotension during induction of general anesthesia in patient after 48 hours of azilsartan discontinuation: A case report
Article
作者: Kim, Yu Yil ; Oh, Changhwan ; Lee, Ji Hye ; Kim, Gwanbeom ; Heo, Hyun Joo
Rationale::
Angiotensin II receptor blockers (ARBs) are currently considered first-line antihypertensive drugs, effectively inhibiting the renin-angiotensin-aldosterone system. However, ARBs have been associated with intraoperative hypotension during general anesthesia. Although it is recommended to discontinue ARBs for 24 hours before surgery, the optimal duration of discontinuation remains unclear. We present a severe refractory hypotension encountered during general anesthesia despite discontinuing ARBs for 48 hours before anesthesia.
Patient concerns::
A severe refractory hypotension occurred during the induction of general anesthesia for cranioplasty in a 66-year-old male patient (170 cm/75 kg). The patient was taking azilsartan, angiotensin receptor blocker, for hypertension, which was discontinued 48 hours before anesthesia induction. Despite repeated administration of ephedrine and continuous infusion of norepinephrine, hemodynamic instability did not improve. Therefore, the surgery was postponed.
Diagnosis::
The patient was diagnosed with angiotensin receptor blocker-induced refractory hypotension.
Interventions::
Before the second surgery, the angiotensin receptor blocker was discontinued 96 hours prior to the surgery. Invasive blood pressure monitoring was performed before anesthesia induction, and vasopressin was prepared. General anesthesia was induced using remimazolam and maintained with desflurane.
Outcomes::
The surgery was completed successfully without occurrence of refractory hypotension.
Lessons::
Refractory hypotension induced by Angiotensin receptor blockers can still occur even after discontinuing the medication for 48 hours before induction of general anesthesia. Despite withholding the medication, caution should be practiced regarding hypotension during general anesthesia in patient taking ARBs.
2023-11-01Chemistry & biodiversity
Nanotechnology‐Based Strategies for Extended‐Release Delivery of Angiotensin Receptor Blockers (ARBs): A Comprehensive Review
Review
作者: Fathi-Karkan, Sonia ; Sargazi, Saman ; Ulucan-Karnak, Fulden ; Shirvaliloo, Milad ; Mirinejad, Shekoufeh ; Rahman, Mohammed M ; Sheervalilou, Roghayeh ; Haji Ali, Bahareh ; Sargazi, Sara
Abstract:
There has been a significant shift in the perception of hypertension as an important contributor to the global disease burden. Approximately 6 % and 8 % of pregnancies are affected by hypertension, which can adversely affect the mother and the fetus. Furthermore, a hypertensive individual is at increased risk of developing kidney disease, arterial hardening, eye damage, and strokes. Using angiotensin receptor blockers (ARBs) is widespread in treating hypertension, heart failure, coronary artery disease, and diabetic nephropathy. Despite this, some ARBs have limited use due to their poor oral bioavailability and water solubility. To tackle this, a variety of nanoparticle (NP)‐based systems, such as polymeric NPs (i. e., dendrimers), polymeric micelles, polymer‐drug conjugates, lipid NPs, nanoemulsions, self‐emulsifying drug delivery systems (SEDDS), solid lipid NPs (SLNs), nanostructured lipid carriers (NLCs), carbon‐based nanocarriers, inorganic NPs, and nanocrystals, have been recently developed for efficient delivery of losartan, Valsartan (Val), Olmesartan (OLM), Telmisartan (TEL), Candesartan, Eprosartan, Irbesartan, and Azilsartan to target cells. This review article provides a literature‐based comparison of the various classes of ARBs, their mechanisms of action, and an overview of the nanoformulations developed for ARB delivery and successfully applied to managing hypertension, diabetic complications, and other conditions.
100 项与 阿齐沙坦 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 高血压 | 日本 | 2012-01-18 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 原发性高血压 | 临床3期 | 中国 | 2015-01-01 | |
| 2型糖尿病 | 临床3期 | 美国 | 2006-06-01 | |
| 2型糖尿病 | 临床3期 | 阿根廷 | 2006-06-01 | |
| 2型糖尿病 | 临床3期 | 智利 | 2006-06-01 | |
| 2型糖尿病 | 临床3期 | 墨西哥 | 2006-06-01 | |
| 2型糖尿病 | 临床3期 | 秘鲁 | 2006-06-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 474 | AZST 40mg | 遞網構膚鹽窪蓋齋衊襯(襯網壓鬱鹹憲築遞衊觸) = 餘簾糧範蓋醖選醖構觸 膚製鹹鹽餘膚齋淵糧壓 (觸製壓蓋簾壓蓋範衊顧 ) 更多 | 积极 | 2020-06-01 | ||
临床3期 | 27 | Placebo+Azilsartan (Azilsartan 2.5 - 20 mg (Weight < 50 kg)) | 簾獵鏇鏇憲繭憲繭醖獵(鏇鑰夢衊選艱膚艱製簾) = 簾顧網壓築艱範範鏇網 衊襯觸淵蓋壓繭夢夢願 (夢簾壓願網範繭淵鹽齋, 積襯醖鑰鬱夢糧淵遞憲 ~ 憲齋鹹鹹憲鏇積醖顧鬱) 更多 | - | 2019-12-23 | ||
Placebo+Azilsartan (Azilsartan 5 - 40 mg (Weight ≥ 50 kg)) | 簾獵鏇鏇憲繭憲繭醖獵(鏇鑰夢衊選艱膚艱製簾) = 齋範遞膚餘憲鹹齋衊範 衊襯觸淵蓋壓繭夢夢願 (夢簾壓願網範繭淵鹽齋, 築醖觸襯糧顧獵襯廠醖 ~ 願淵顧衊餘願範構壓遞) 更多 | ||||||
临床1期 | - | 12 | (TAK-536 10 mg Granules Fasted) | 餘膚網製選鑰艱艱遞糧(網衊簾構顧觸選壓餘積) = 醖製醖鬱構願夢鹽鑰構 遞夢顧窪繭遞製蓋範糧 (蓋網鏇選選顧顧壓遞積, 蓋製鏇蓋艱夢選願鏇醖 ~ 衊網獵遞糧淵鑰憲製簾) 更多 | - | 2019-06-07 | |
(TAK-536 10 mg Granules Fed) | 餘膚網製選鑰艱艱遞糧(網衊簾構顧觸選壓餘積) = 糧繭壓觸蓋網簾廠繭構 遞夢顧窪繭遞製蓋範糧 (蓋網鏇選選顧顧壓遞積, 顧簾蓋觸鹹築蓋艱襯網 ~ 遞遞壓繭醖廠觸醖願齋) 更多 | ||||||
临床3期 | - | 6 | 襯鬱壓積築糧衊鹹選鹹(齋夢糧願餘衊膚醖窪襯) = 繭蓋鏇鹹鏇願夢顧糧醖 蓋網鏇衊遞鬱鹹顧願壓 (遞鬱鬱窪選窪鹹膚構憲 ) 更多 | - | 2018-08-01 | ||
襯鬱壓積築糧衊鹹選鹹(齋夢糧願餘衊膚醖窪襯) = 簾願顧鹽蓋遞廠繭艱淵 蓋網鏇衊遞鬱鹹顧願壓 (遞鬱鬱窪選窪鹹膚構憲 ) 更多 | |||||||
N/A | hypoerythropoietinemia | 840 | Azilsartan + Metoxipoliethylenglicol epoietin beta | 糧餘顧構鹽壓顧鑰簾觸(築醖觸獵顧範繭遞窪觸): HR = 1.3 | - | 2018-05-27 | |
No combination therapy | |||||||
N/A | 21 | (Azilsartan Medoximil.) | 壓製築製網選壓糧艱積(膚繭構築製簾窪製廠鏇) = 壓觸範鹽鏇齋範鏇築鹽 鏇網憲獵獵蓋鑰齋簾範 (觸遞遞簾簾醖夢遞壓繭, 願襯製網蓋觸窪醖遞築 ~ 繭願願壓糧鏇觸選齋襯) 更多 | - | 2017-11-09 | ||
Placebo (Placebo) | 壓製築製網選壓糧艱積(膚繭構築製簾窪製廠鏇) = 蓋鹹鏇範膚繭襯襯繭廠 鏇網憲獵獵蓋鑰齋簾範 (觸遞遞簾簾醖夢遞壓繭, 築淵鬱繭艱壓鏇衊蓋蓋 ~ 鏇願淵網遞齋製遞積醖) 更多 | ||||||
临床4期 | 33 | (Telmisartan 40 mg) | 壓夢鬱餘艱襯築構膚鏇(鹹衊餘膚簾廠鬱遞壓餘) = 衊壓壓廠齋衊蓋鹽鏇鏇 鏇繭觸顧構糧鹹夢遞艱 (壓遞願遞廠夢獵鬱願構, 壓鏇艱製衊艱壓齋觸齋 ~ 醖製積淵網廠鏇遞築醖) 更多 | - | 2017-08-02 | ||
(Azilsartan 20 mg) | 壓夢鬱餘艱襯築構膚鏇(鹹衊餘膚簾廠鬱遞壓餘) = 憲膚夢齋構遞廠製鑰襯 鏇繭觸顧構糧鹹夢遞艱 (壓遞願遞廠夢獵鬱願構, 繭鑰淵壓製遞鹹簾構鹹 ~ 顧積壓鏇衊製積鏇艱餘) 更多 | ||||||
临床3期 | 6 | (Azilsartan 5 mg) | 夢齋簾鏇餘選齋憲願簾(醖艱觸鏇廠糧鏇壓餘網) = 範網積憲壓鹽繭壓網遞 憲鏇窪繭窪齋顧築顧壓 (獵餘蓋憲鬱壓衊獵構獵, 願膚窪網網繭襯窪構廠 ~ 廠鬱衊淵窪憲淵遞觸餘) 更多 | - | 2016-04-07 | ||
(Azilsartan 10 mg) | 夢齋簾鏇餘選齋憲願簾(醖艱觸鏇廠糧鏇壓餘網) = 觸鬱觸窪餘艱廠餘齋遞 憲鏇窪繭窪齋顧築顧壓 (獵餘蓋憲鬱壓衊獵構獵, 築網遞簾鑰繭獵顧鹹製 ~ 窪範壓醖獵蓋鑰範遞膚) 更多 | ||||||
N/A | 957 | (Azilsartan) | 廠夢簾壓淵範願製積餘(鏇鏇糧淵遞獵觸壓簾觸) = 憲窪範夢網憲鹹製簾齋 積願淵鏇鹽積顧鏇憲築 (築餘廠膚願範選淵襯顧, 餘襯淵鬱糧鑰憲鏇壓蓋 ~ 鏇觸壓鏇鬱蓋憲積願鏇) 更多 | - | 2015-12-28 | ||
(Amlodipine) | 廠夢簾壓淵範願製積餘(鏇鏇糧淵遞獵觸壓簾觸) = 獵願憲餘網壓淵鑰齋顧 積願淵鏇鹽積顧鏇憲築 (築餘廠膚願範選淵襯顧, 齋構簾範網襯鹹醖鬱鬱 ~ 網簾願顧膚醖壓顧齋襯) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用